Two of these targeting peptides, LyP-1 and iRGD, appear to bind to endothelial cells within tumors, as well as tumor cells themselves, and can also facilitate the uptake of bound cargo, including siRNA, directly into tumor cells [27–29]. The gene discussed is PTPN22; the disease is neoplasm.